Cat. No.: HY-106139

Bimosiamose

(Synonyms: TBC-1269)

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC₅₀s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively. Bimosiamose has anti-inflammatory effects.

For research use only. We do not sell to patients.

Purity: 98.82%
CAS No.: 187269-40-5
Formula: C₄₆H₅₄O₁₆
Molecular Weight:862.91

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Bimosiamose Chemical Structure

CAS No.: 187269-40-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

IC50: 88 μM (E-selectin), 20 μM (P-selectin), 86 μM (L-selectin)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
HL-60	IC₅₀	70 μM Compound: TBC1269	Inhibition of P-selectin-mediated adhesion of HL60 cells Inhibition of P-selectin-mediated adhesion of HL60 cells	[PMID: 17201408]
HL-60	IC₅₀	70 μM Compound: TBC-1269	Inhibition of P-selectin in human HL-60 cells Inhibition of P-selectin in human HL-60 cells	[PMID: 20718494]

In Vitro

Bimosiamose (TBC-1269) operates by inhibiting neutrophil recruitment to the site of inflammation through blocking the initial rolling phase of recruitment. Bimosiamose (TBC-1269) inhibits cell recruitment and does not possess any cytotoxic effect on neutrophils^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Bimosiamose (TBC-1269; 25 mg/kg; intravenous injection; Sprague-Dawley rats) treatment shows a significant increase in survival. Best overall survival, 70%, is observed when TBC-1269 is administered 15 minutes before reperfusion, and also shows a marked decrease in liver enzyme levels at 6 hours after reperfusion. Neutrophil migration is also significantly ameliorated (81%). The histologic damage scores is also improved^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley rats (200-225g) with ischemia and reperfusion (I/R)^[1]
Dosage:

25 mg/kg
Administration:

Intravenous injection
Result:

Showed a significant increase in survival compared with controls.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 187269-40-5
Appearance Solid
Molecular Weight 862.91
Formula C₄₆H₅₄O₁₆
Color White to off-white
SMILES

OC[C@H]([C@@H](O)[C@H](O)[C@@H]1O)O[C@@H]1OC(C=C2)=C(C3=CC(CC(O)=O)=CC=C3)C=C2CCCCCCC(C=C4)=CC(C5=CC(CC(O)=O)=CC=C5)=C4O[C@H]6O[C@@H]([C@@H](O)[C@H](O)[C@@H]6O)CO
Synonyms

TBC-1269
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Short-chain acyl-CoA dehydrogenase initiates mtDNA demethylation and leakage to fuel antitumor immunity in colorectal cancer. [Abstract]

2026 Mar 26;11(1):113. PMID: 41888107
Mar Drugs

Exploring the Inhibitory Effects of Fucosylated Chondroitin Sulfate (FCS) Oligosaccharide Isolated from Stichopus horrens and the Derivatives on P-Selectin. [Abstract]

2025 May 30;23(6):236. PMID: 40559645
Platelets

Method article: an in vitro blood flow model to advance the study of platelet adhesion utilizing a damaged endothelium. [Abstract]

2022 Jul 4;33(5):692-699. PMID: 34927530
University of Michigan

2022 May.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (115.89 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

0.1 M NaOH : 25 mg/mL (28.97 mM; ultrasonic and adjust pH to 10 with NaOH)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1589 mL

5.7943 mL

11.5887 mL

5 mM

0.2318 mL

1.1589 mL

2.3177 mL

10 mM

0.1159 mL

0.5794 mL

1.1589 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 2.5 mg/mL (2.90 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Palma-Vargas JM, et al. Small-molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion. J Am Coll Surg. 1997 Oct;185(4):365-72. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
0.1 M NaOH / DMSO	1 mM	1.1589 mL	5.7943 mL	11.5887 mL	28.9717 mL
	5 mM	0.2318 mL	1.1589 mL	2.3177 mL	5.7943 mL
	10 mM	0.1159 mL	0.5794 mL	1.1589 mL	2.8972 mL
	15 mM	0.0773 mL	0.3863 mL	0.7726 mL	1.9314 mL
	20 mM	0.0579 mL	0.2897 mL	0.5794 mL	1.4486 mL
	25 mM	0.0464 mL	0.2318 mL	0.4635 mL	1.1589 mL
DMSO	30 mM	0.0386 mL	0.1931 mL	0.3863 mL	0.9657 mL
	40 mM	0.0290 mL	0.1449 mL	0.2897 mL	0.7243 mL
	50 mM	0.0232 mL	0.1159 mL	0.2318 mL	0.5794 mL
	60 mM	0.0193 mL	0.0966 mL	0.1931 mL	0.4829 mL
	80 mM	0.0145 mL	0.0724 mL	0.1449 mL	0.3621 mL
	100 mM	0.0116 mL	0.0579 mL	0.1159 mL	0.2897 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Bimosiamose

Immunology/Inflammation Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Targeted Diversity Library

Human Metabolite Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Bimosiamose

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Bimosiamose

Immunology/Inflammation Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Targeted Diversity Library

Human Metabolite Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Bimosiamose

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Bimosiamose Related Classifications

HY-106139 Related Classifications